Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020771 | 1.00 | HDAC8 (0.43) | HDAC8GRIN2BOPRK1ALDH1A1TDP1 | |
| SCHEMBL29630894 | 0.81 | CA1 (0.51) | HDAC8GRIN2BALDH1A1 | |
| SCHEMBL13213509 | 0.81 | CA1 (0.51) | HDAC8GRIN2BALDH1A1 | |
| SCHEMBL3009533 | 0.79 | MTNR1A (0.36) | GRIN2BMTNR1AMTNR1B | |
| SCHEMBL20722710 | 0.79 | MTNR1A (0.35) | HDAC8OPRK1MTNR1AMTNR1B | |
| SCHEMBL3020927 | 0.78 | HDAC8 (0.31) | HDAC8 | |
| SCHEMBL3020933 | 0.78 | HDAC8 (0.31) | HDAC8 | |
| SCHEMBL3020855 | 0.78 | CYP1A2 (0.37) | HDAC8OPRK1ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL3020851 | 0.78 | CYP1A2 (0.37) | HDAC8OPRK1ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL3016071 | 0.76 | MTNR1A (0.35) | ALDH1A1SMN1; SMN2LMNAMAPTMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| EP-2139898-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | HDAC8 110/4885GRIN2B 3388/4885OPRK1 3379/4885 |
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | HDAC8 610/4885GRIN2B 1764/4885OPRK1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.